BACKGROUND: Intensive statin therapy decreases mortality and incidence of coronary events in patients after acute coronary syndrome (ACS). Recently it has been reported that spontaneous lipid levels remain clinically stable during ACS. The immediate influence of lipid levels by high-dose statin therapy initiated at admission in ACS patients is, however, not clear. METHODS: We have analyzed a group of 114 patients with ACS (mean age 63.7; females 25.4%). Atorvastatin 80 mg was administered at admission and then once daily for the rest of hospitalization. The levels of total cholesterol (TC), LDL-cholesterol (LDL), HDL-cholesterol (HDL), and triglycerides (TG) were measured at admission (D0), and then every morning of hospitalization (D1, D2). RESULTS: The mean entry values (D0) of TC, LDL, HDL and TG (in mmol/L) were 5.24, 3.26, 1.07 and 1.31, respectively. The therapy with atorvastatin 80 mg resulted in a decrease of TC levels in the first morning (D1) by 6.1% and in the second morning (D2) by 13.2% (p<0.001 for all comparisons with the entry value D0); LDL was decreased by 5.8% (D1) and 15.6% (D2) (p<0.001 vs. D0); the level of HDL was decreased by 7.5% (D1) and 12.1% (D2) (p<0.001 vs. D0). In contrast, the TG level was higher in the first morning (D1) by 20.6% and in the following morning (D2) by 25.5% (p<0.05 vs. D0). CONCLUSIONS: We have shown that intensive statin therapy started at admission in ACS patients has a highly significant, immediate effect on all monitored lipid levels. Since TC and LDL levels were decreased as predicted, reduction in HDL and increase in TG levels suggest a different acute effect of high-dose statin on lipid levels in comparison with long-term treatment of ACS patients.

Cardiovascular Center Department of Cardiology Na Homolce Hospital Prague Czech Republic

Zobrazit více v PubMed

Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama. 2001;285:1711–1718. doi: 10.1001/jama.285.13.1711. PubMed DOI

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504. doi: 10.1056/NEJMoa040583. PubMed DOI

de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama. 2004;292:1307–1316. doi: 10.1001/jama.292.11.1307. PubMed DOI

Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814–1821. doi: 10.1001/archinte.166.17.1814. PubMed DOI

Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. Cmaj. 2008;178:576–584. PubMed PMC

Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, Martinkovicova L, Vojacek J. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Mol Cell Biochem. 2007;306:19–23. doi: 10.1007/s11010-007-9549-8. PubMed DOI

Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–616. doi: 10.1016/j.amjcard.2005.04.029. PubMed DOI

Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, Mates M, Kvapil M, Kettner J, Wiendl M. Fluvastatin in the first-line therapy of Acute Coronary Syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (The FACS-trial) Trials. 2010. PubMed PMC

Fyfe T, Baxter RH, Cochran KM, Booth EM. Plasma-lipid changes after myocardial infarction. Lancet. 1971;2:997–1001. doi: 10.1016/S0140-6736(71)90322-9. PubMed DOI

Sniderman AD, Teng B. Predictable changes in low density lipoprotein composition after acute myocardial infarction. Atherosclerosis. 1977;27:361–368. doi: 10.1016/0021-9150(77)90046-6. PubMed DOI

Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933–940. doi: 10.1016/0735-1097(93)90213-K. PubMed DOI

Fresco C, Maggioni AP, Signorini S, Merlini PA, Mocarelli P, Fabbri G, Lucci D, Tubaro M, Gattone M, Schweiger C. Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. Ital Heart J. 2002;3:587–592. PubMed

Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440–1445. doi: 10.1016/j.jacc.2007.11.075. PubMed DOI

Michelena HI, Osorio LA, Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol. 2005;101:111–114. doi: 10.1016/j.ijcard.2004.08.021. PubMed DOI

Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta. 2006;368:168–172. doi: 10.1016/j.cca.2005.12.040. PubMed DOI

Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000;36:617–621. doi: 10.1097/00005344-200011000-00011. PubMed DOI

Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol. 2003;26:472–476. doi: 10.1002/clc.4960261008. PubMed DOI PMC

Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001;104:376–379. doi: 10.1161/hc2901.094094. PubMed DOI

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers

Statins as first-line therapy for acute coronary syndrome?